Stroke remains a leading cause of morbidity worldwide, with limited pharmacological options beyond thrombolysis and thrombectomy in the acute phase. Granulocyte colony-stimulating factor (G-CSF), a ...
The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis TrACER was a cluster randomized ...
Substance use disorder (SUD) is a chronic neurobiological-based medical illness contributing to almost 6% of all deaths worldwide 1. In recent years, it has been confirmed that SUDs are associated ...
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of ...
Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim ...
29 Phase I Stage III/IV melanoma pts (16) Intradermal injection of sargramostim into melanoma lesions and normal skin (as a control) for 10 days at four dose levels (10, 20, 40, and 80 µg/day) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results